In her first speech since becoming Director of the Federal Trade Commission’s Bureau of Competition, Deborah Feinstein highlighted five benefits arising from addressing antitrust violations through consent orders and dispelled a number of “persistent myths” about their use. While emphasizing the FTC “employs a rigorous case-by-case approach to law enforcement decisions,” Director Feinstein explained that
More Posts
FTC Investigations of Technology Transactions – Am I at Risk?
“Highly Unusual” Circumstances End FTC Challenge to Phoebe Putney Acquisition
FTC Investigations of Pharma and Medical Device Transactions – Am I at Risk?
FTC Investigations of Provider Healthcare Transactions: Am I at Risk?
FTC Investigations of Energy and Chemical Transactions – Am I at Risk?
Will the FTC Investigate My Provider Healthcare Transaction?
Is the FTC Setting Its Sights on Consummated Hospital and Physician Mergers?
Are Consummated Hospital and Physician Mergers Now in the FTC’s Crosshairs?
Supreme Court Rules That “Pay for Delay” Generic Drug Patent Settlements Aren’t Shielded From Antitrust Liability
Subscribe: Subscribe via RSS
Firm/Org